Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A6383
Buy Now

Market Overview:

The 7 major Chimeric Antigen Receptor (CAR) T-Cell Therapy markets reached a value of US$ 3,589.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11,282.5 Million by 2034, exhibiting a growth rate (CAGR) of 10.85% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 3,589.7 Million
Market Forecast in 2034
US$ 11,282.5 Million
Market Growth Rate 2024-2034
10.85%


Chimeric Antigen Receptor (CAR) T-Cell Therapy market is currently driven by factors such as the rising incidence of cancer, a strong drug pipeline, rising number of healthcare settings that administer CAR T, improving safety and efficacy of current and emerging therapies, etc. CAR T-cell therapies have a potential to transform cancer treatment by using the immune system to fight diseases. CAR T therapy requires genetically engineering T cells (either a patient’s own or a donor’s) to express a chimeric antigen receptor that targets a particular tumor antigen.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

The biggest factor catalyzing the growth of the market is the strong efficacy of these treatment. For instance, pediatric and young adult patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) achieved an overall remission rate of 90 percent during the first 12 months with treatment with an anti-CD19 autologous CAR T therapy. However, in spite of, the convincing efficacy data in clinical trials, there are a number of challenges impacting the commercialization of CAR Ts. These challenges include complex and costly manufacturing and supply chain, lengthy and logistically challenging patient journey, and reimbursement challenges. The (CAR) T-Cell Therapy market is set to be a transformative therapy in cancer care, but unleashing its potential will require placing strategic bets. Technological advances and manufacturing innovations are rapidly improving - with the prospects for CAR T to not only treat niche liquid tumors but a broader range of solid and liquid tumors in the near future. Market players that are able to make intelligent investments can significantly expand the number of patients they treat as well as the success rates of their therapies.

IMARC Group’s new report "Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy across the seven major markets. According to the report the United States has the largest patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy and also represents the largest market for Chimeric Antigen Receptor (CAR) T-Cell Therapy treatments. Furthermore, the current Chimeric Antigen Receptor (CAR) T-Cell Therapy treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Sales of Various Drugs Across the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Reimbursement Scenario in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

Competitive Landscape:

This report also provides a detailed analysis of the current Chimeric Antigen Receptor (CAR) T-Cell Therapy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance


Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Breyanzi (Lisocabtagene maraleucel) Juno Therapeutics
Abecma (Idecabtagene vicleucel) 2seventy bio
Carvykti (Ciltacabtagene autoleucel) Janssen Biotech/Nanjing Legend Biotech
Kymriah (Tisagenlecleucel) Novartis/University of Pennsylvania
Tecartus (Brexucabtagene autoleucel) Kite Pharma
PHE 885 Novartis Pharmaceuticals
TT 11 Tessa Therapeutics
Descartes 08 Cartesian Therapeutics
Descartes 011 Cartesian Therapeutics
BCMA-targeted cell therapy Arcellx


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the Chimeric Antigen Receptor (CAR) T-Cell Therapy market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
  • What was the country-wise size of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market across the seven major markets in 2023 and how will it look like in 2034?
  • What is the growth rate of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market?


Epidemiology Insights

  • What is the size of the Chimeric Antigen Receptor (CAR) T-Cell Therapy patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) of Chimeric Antigen Receptor (CAR) T-Cell Therapy across the seven major markets?
  • What are the key factors driving the epidemiological trend of Chimeric Antigen Receptor (CAR) T-Cell Therapy?
  • What will be the growth rate of Chimeric Antigen Receptor (CAR) T-Cell Therapy patients across the seven major markets?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their market performance?
  • What are the key pipeline Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their efficacies?
  • How safe are the late-stage pipeline Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their efficacies?
  • What are the current treatment guidelines for Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs across the seven major markets?
  • Who are the key companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Chimeric Antigen Receptor (CAR) T-Cell Therapy market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More